George

Biography

He is  an infectious diseases physician by training, began his pharmaceutical career in anti-infective drug development at Rhone-Poulenc Rorer, later Aventis.  He founded his consultancy firm, Talbot Advisors LLC, in 2000. Dr. Talbot served as EVP and CMO of Cerexa (purchased by Forest Laboratories in 2007), and worked closely with Calixa Therapeutics (acquired by Cubist Pharmaceuticals, 2009) and Durata Therapeutics (purchased by Actavis Plc, 2014). In addition to his role on Nabriva’s Supervisory Board, he chairs its Clinical Advisory Board. Dr. Talbot was a founding member of IDSA's Antimicrobial Availability Task Force ("Bad Bugs, No Drugs"), and co-Chairs the ABSSSI/CABP and HABP/VABP Project Teams at the Biomarkers Consortium of the Foundation of the National Institutes of Health. He is  an infectious diseases physician by training, began his pharmaceutical career in anti-infective drug development at Rhone-Poulenc Rorer, later Aventis.  He founded his consultancy firm, Talbot Advisors LLC, in 2000. Dr. Talbot served as EVP and CMO of Cerexa (purchased by Forest Laboratories in 2007), and worked closely with Calixa Therapeutics (acquired by Cubist Pharmaceuticals, 2009) and Durata Therapeutics (purchased by Actavis Plc, 2014). In addition to his role on Nabriva’s Supervisory Board, he chairs its Clinical Advisory Board. Dr. Talbot was a founding member of IDSA's Antimicrobial Availability Task Force ("Bad Bugs, No Drugs"), and co-Chairs the ABSSSI/CABP and HABP/VABP Project Teams at the Biomarkers Consortium of the Foundation of the National Institutes of Health.

Research Interest

Pharmaceutics.